Predictors of response, progression‐free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high‐risk neuroblastoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pediatric Blood & Cancer

• Publication date

  2018-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.26940PMID 29350464PMCID PMC7456604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• COVD-28. IMPACT OF COVID‐19 IN CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS IN ARGENTINA. REPORT FROM THE NATIONAL PEDIATRIC CANCER REGISTRY, ROHA NETWORK

  2020cited by this paper
• Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

  2017cited by this paper
• Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group

  2017cited by this paper
• Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements

  2016cited by this paper
• Childhood Neuroblastoma: Incidence and Survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000–2012

  2016influential reference
• A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High‐Risk Neuroblastoma

  2016cited by this paper
• Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

  2015cited by this paper
• 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

  2015cited by this paper
• Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study

  2014cited by this paper
• Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium

  2013cited by this paper
• 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.

  2013cited by this paper
• Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

  2013cited by this paper
• The Analysis of Survival Data

  2012cited by this paper
• Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

  2012cited by this paper
• Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial

  2012cited by this paper
• Cancer Therapy : Clinical Phase I Study of Vincristine , Irinotecan , and 131 I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma : A New Approaches to Neuroblastoma Therapy Trial

  2012cited by this paper
• Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

  2012cited by this paper
• Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.

  2012cited by this paper
• Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study

  2011cited by this paper
• Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

  2011cited by this paper
• A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study

  2011cited by this paper
• Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

  2009cited by this paper
• Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

  2009cited by this paper
• Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

  2009cited by this paper
• Disease control intervals in high‐risk neuroblastoma

  2008cited by this paper
• Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

  2006cited by this paper
• Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

  2003cited by this paper
• Stata Statistical Software: Release 7.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995.

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?

  1997cited by this paper
• Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma.

  1995cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

  1993cited by this paper
• Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.

  1993cited by this paper
• Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment.

  1993cited by this paper
• The value of bone marrow trephine biopsy in the diagnosis of metastatic neuroblastoma.

  1985cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• The analysis and selection of variables in linear regression

  1976cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• THE NATURAL DURATION OF CANCER

  1925cited by this paper
• THE NATURAL DURATION OF CANCER

  1924cited by this paper

• A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

  2026cites this paper
• A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma

  2025cites this paper
• Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

  2025influential citation
• Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

  2025cites this paper
• Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

  2023influential citation
• Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

  2023cites this paper
• Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131I‐MIBG in patients with relapsed/refractory neuroblastoma

  2023cites this paper
• miR-21 Targets Long Noncoding RNA PCAT29 to Promote Cell Proliferation in Neuroblastoma.

  2022cites this paper
• Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

  2022cites this paper
• Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

  2021cites this paper
• Bone and bone marrow involvement in neuroblastoma

  2020cites this paper
• A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis

  2019cites this paper
• 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma

  2019cites this paper
• Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

  2018cites this paper